EGFR and non-small cell lung carcinoma: Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is an oral targeted anticancer drug for non-small cell lung cancer (NSCLC) treatment, and showing a significant improvement of survival in NSCLC [32].